Amalgamated Bank Boosts Stake in Natera, Inc. $NTRA

Amalgamated Bank raised its position in Natera, Inc. (NASDAQ:NTRA) by 23.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,263 shares of the medical research company’s stock after buying an additional 1,970 shares during the period. Amalgamated Bank’s holdings in Natera were worth $1,734,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NTRA. Price T Rowe Associates Inc. MD increased its stake in Natera by 56.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after buying an additional 3,795,315 shares during the last quarter. Nuveen LLC purchased a new stake in Natera in the 1st quarter valued at about $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Natera by 140.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company’s stock valued at $177,298,000 after buying an additional 732,156 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Natera by 9.9% in the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock valued at $1,041,055,000 after buying an additional 660,538 shares during the last quarter. Finally, Ninety One UK Ltd increased its stake in Natera by 149.1% in the 2nd quarter. Ninety One UK Ltd now owns 562,985 shares of the medical research company’s stock valued at $95,111,000 after buying an additional 336,985 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

NTRA has been the subject of a number of research reports. Zacks Research downgraded shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Monday, October 20th. Piper Sandler reissued an “overweight” rating and set a $220.00 target price (up from $210.00) on shares of Natera in a research report on Monday, August 11th. Wells Fargo & Company initiated coverage on shares of Natera in a research report on Monday, September 22nd. They set an “equal weight” rating and a $175.00 target price for the company. Evercore ISI raised shares of Natera to a “strong-buy” rating and set a $170.00 target price for the company in a research report on Monday, July 28th. Finally, BNP Paribas raised shares of Natera to a “hold” rating and set a $172.00 target price for the company in a research report on Monday, October 27th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $194.89.

Insider Activity at Natera

In other news, CFO Michael Burkes Brophy sold 1,867 shares of the firm’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $190.64, for a total transaction of $355,924.88. Following the sale, the chief financial officer owned 64,126 shares in the company, valued at approximately $12,224,980.64. This trade represents a 2.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider John Fesko sold 928 shares of the firm’s stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $191.46, for a total transaction of $177,674.88. Following the sale, the insider owned 150,699 shares in the company, valued at approximately $28,852,830.54. This trade represents a 0.61% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 224,889 shares of company stock worth $43,232,062. Corporate insiders own 5.63% of the company’s stock.

Natera Trading Up 1.8%

NTRA opened at $199.92 on Thursday. The company has a 50 day moving average of $176.51 and a 200 day moving average of $163.03. Natera, Inc. has a 12 month low of $123.61 and a 12 month high of $203.23. The company has a market cap of $27.44 billion, a PE ratio of -104.67 and a beta of 1.75.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million for the quarter, compared to analysts’ expectations of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business’s quarterly revenue was up 32.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.30) EPS. Research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.